PDF(Pubmed)
Abstract：
BACKGROUND: Gastric cancer (GC) is the sixth most common cancer and third leading cause of cancer-related deaths worldwide. Current treatments mainly rely on surgery- and chemotherapy-based systemic; however, the prognosis remains poor for advanced disease. Recent studies have suggested that immunotherapy has significant potential in cancer therapy; thus, GC immunotherapy may improve quality of life and survival for patients with this disease.
OBJECTIVE: To provide a comprehensive overview of the knowledge structure and research hotspots of GC immunotherapy.
METHODS: We conducted a bibliometric analysis of publications on immunotherapy related to GC in the Web of Science Core Collection database. We analyzed 2013 pub-lications from 1999 to February 1, 2023, using the VOSviewer and CiteSpace software. We assessed publication and citation distributions using the WoS platform and explored research countries, institutions, journals, authors, references, and keywords (co-occurrence, timeline view, and burst analysis). In addition, we examined 228 trials on immunotherapy, 137 on adoptive cell therapy, 274 on immune checkpoint inhibitors (ICIs), and 23 on vaccines from ClinicalTrials.gov and the International Clinical Trials Registry Platform. The Impact Index Per Article for the top ten high-cited papers collected from Reference Citation Analysis (RCA) are presented.
RESULTS: Our bibliometric analysis revealed that the study of immunotherapy in GC has developed rapidly in recent years. China accounted for almost half the publications, followed by the United States. The number of publications in recent years has been growing continuously, and most institutions and authors with the most publications are from China. The main keywords or clusters identified were \"tumor microenvironment\", \"adoptive immunotherapy\", \"dendritic therapy\", and \"microsatellite instability\".
CONCLUSIONS: Our analysis of 2013 publications indicated that immunotherapy for GC has led to several new developments in recent years. Considerable progress has been made in vaccinations, immune checkpoint therapy, and adoptive cellular therapy. In particular, ICIs and chimeric antigen receptor T-cells are novel options for the treatment of GC. We suggest that the combination of ICIs, chemotherapy, targeted therapy, and other immunotherapies should be the primary research direction in the future.
OBJECTIVE: To provide a comprehensive overview of the knowledge structure and research hotspots of GC immunotherapy.
METHODS: We conducted a bibliometric analysis of publications on immunotherapy related to GC in the Web of Science Core Collection database. We analyzed 2013 pub-lications from 1999 to February 1, 2023, using the VOSviewer and CiteSpace software. We assessed publication and citation distributions using the WoS platform and explored research countries, institutions, journals, authors, references, and keywords (co-occurrence, timeline view, and burst analysis). In addition, we examined 228 trials on immunotherapy, 137 on adoptive cell therapy, 274 on immune checkpoint inhibitors (ICIs), and 23 on vaccines from ClinicalTrials.gov and the International Clinical Trials Registry Platform. The Impact Index Per Article for the top ten high-cited papers collected from Reference Citation Analysis (RCA) are presented.
RESULTS: Our bibliometric analysis revealed that the study of immunotherapy in GC has developed rapidly in recent years. China accounted for almost half the publications, followed by the United States. The number of publications in recent years has been growing continuously, and most institutions and authors with the most publications are from China. The main keywords or clusters identified were \"tumor microenvironment\", \"adoptive immunotherapy\", \"dendritic therapy\", and \"microsatellite instability\".
CONCLUSIONS: Our analysis of 2013 publications indicated that immunotherapy for GC has led to several new developments in recent years. Considerable progress has been made in vaccinations, immune checkpoint therapy, and adoptive cellular therapy. In particular, ICIs and chimeric antigen receptor T-cells are novel options for the treatment of GC. We suggest that the combination of ICIs, chemotherapy, targeted therapy, and other immunotherapies should be the primary research direction in the future.
摘要：
背景：胃癌（GC）是全球第六大最常见的癌症，也是癌症相关死亡的第三大原因。目前的治疗主要依赖于手术和化疗为基础的全身;然而，晚期疾病的预后仍然较差。最近的研究表明，免疫疗法在癌症治疗中具有巨大的潜力；因此，GC免疫治疗可改善该疾病患者的生活质量和生存率。
目的：对GC免疫治疗的知识结构和研究热点进行全面综述。
方法：我们对WebofScienceCoreCollection数据库中与GC相关的免疫治疗出版物进行了文献计量分析。我们使用VOSviewer和CiteSpace软件分析了1999年至2023年2月1日的2013年出版物。我们使用WoS平台评估出版物和引文分布，并探索研究国家，机构,期刊,作者,参考文献,和关键字(共现，时间线视图,和突发分析)。此外,我们检查了228项免疫治疗试验，137关于过继细胞疗法，274关于免疫检查点抑制剂（ICIs），和23来自ClinicalTrials.gov和国际临床试验注册平台的疫苗。介绍了从参考引文分析（RCA）收集的十大高被引论文的每篇影响指数。
结果：我们的文献计量分析显示，近年来GC中免疫治疗的研究发展迅速。中国几乎占出版物的一半，其次是美国。近年来出版物数量持续增长,和大多数机构和作者与最多的出版物来自中国。确定的主要关键词或簇是“肿瘤微环境”，“过继免疫疗法”，“树突疗法”，和“微卫星不稳定性”。
结论：我们对2013年出版物的分析表明，近年来GC的免疫疗法带来了一些新的发展。在接种疫苗方面取得了相当大的进展,免疫检查点疗法，和过继细胞疗法。特别是,ICIs和嵌合抗原受体T细胞是治疗GC的新选择。我们建议ICI的组合，化疗,靶向治疗,和其他免疫疗法应该是未来的主要研究方向。
目的：对GC免疫治疗的知识结构和研究热点进行全面综述。
方法：我们对WebofScienceCoreCollection数据库中与GC相关的免疫治疗出版物进行了文献计量分析。我们使用VOSviewer和CiteSpace软件分析了1999年至2023年2月1日的2013年出版物。我们使用WoS平台评估出版物和引文分布，并探索研究国家，机构,期刊,作者,参考文献,和关键字(共现，时间线视图,和突发分析)。此外,我们检查了228项免疫治疗试验，137关于过继细胞疗法，274关于免疫检查点抑制剂（ICIs），和23来自ClinicalTrials.gov和国际临床试验注册平台的疫苗。介绍了从参考引文分析（RCA）收集的十大高被引论文的每篇影响指数。
结果：我们的文献计量分析显示，近年来GC中免疫治疗的研究发展迅速。中国几乎占出版物的一半，其次是美国。近年来出版物数量持续增长,和大多数机构和作者与最多的出版物来自中国。确定的主要关键词或簇是“肿瘤微环境”，“过继免疫疗法”，“树突疗法”，和“微卫星不稳定性”。
结论：我们对2013年出版物的分析表明，近年来GC的免疫疗法带来了一些新的发展。在接种疫苗方面取得了相当大的进展,免疫检查点疗法，和过继细胞疗法。特别是,ICIs和嵌合抗原受体T细胞是治疗GC的新选择。我们建议ICI的组合，化疗,靶向治疗,和其他免疫疗法应该是未来的主要研究方向。
